Valderrábano Fernando, Hörl Walter H, Macdougall Iain C, Rossert Jérôme, Rutkowski Boleslaw, Wauters Jean-Pierre
Servicio Nefrología, Hospital Gregorio Marañon, Madrid, Spain.
Nephrol Dial Transplant. 2003 Jan;18(1):89-100. doi: 10.1093/ndt/18.1.89.
The PRE-dialysis survey on anaemia management (PRESAM) was designed to assess the care given to pre-dialysis patients in the 12 months before haemodialysis or peritoneal dialysis, with emphasis on anaemia management.
For this epidemiological study, a retrospective chart review was conducted for patients who started haemodialysis or peritoneal dialysis between 1 August, 1999 and 6 April, 2000. All adult patients who entered one of the 779 participating centres in 21 European countries, Israel or South Africa were included, except for patients who underwent dialysis only during an acute episode. In addition to demographic characteristics, the study examined the prevalence of anaemia, anaemia management including the use of iron supplementation and epoetin, source of referral to the dialysis centre, comorbidities and major clinical events.
A total of 4333 new dialysis patients were included in the survey. At the first visit to the dialysis centre, 68% of the patients had a haemoglobin (Hb) concentration < or = 11.0 g/dl; Hb concentration was positively correlated with creatinine clearance rate (r = 0.43, P < 0.01). Patients who received epoetin had a mean Hb concentration of 8.8 g/dl at the start of epoetin treatment, and 96% of these patients had an Hb concentration < or = 11.0 g/dl. Only 26.5% of the patients received epoetin before dialysis. The length of time under the care of a nephrologist was associated with meeting the European Best Practice Guidelines (EBPG) target Hb concentration, as well as receiving epoetin.
Few pre-dialysis patients met the EBPG target for Hb concentration, despite regular nephrology care.
透析前贫血管理调查(PRESAM)旨在评估在血液透析或腹膜透析前12个月内给予透析前患者的护理情况,重点是贫血管理。
对于这项流行病学研究,对1999年8月1日至2000年4月6日开始进行血液透析或腹膜透析的患者进行了回顾性病历审查。纳入了所有进入21个欧洲国家、以色列或南非的779个参与中心之一的成年患者,但仅在急性发作期间接受透析的患者除外。除人口统计学特征外,该研究还检查了贫血的患病率、贫血管理情况,包括铁补充剂和促红细胞生成素的使用、转诊至透析中心的来源、合并症和主要临床事件。
共有4333名新透析患者纳入调查。在首次就诊于透析中心时,68%的患者血红蛋白(Hb)浓度≤11.0 g/dl;Hb浓度与肌酐清除率呈正相关(r = 0.43,P < 0.01)。接受促红细胞生成素治疗的患者在开始促红细胞生成素治疗时的平均Hb浓度为8.8 g/dl,其中96%的患者Hb浓度≤11.0 g/dl。只有26.5%的患者在透析前接受了促红细胞生成素治疗。肾病专家护理的时间长短与达到欧洲最佳实践指南(EBPG)的目标Hb浓度以及接受促红细胞生成素治疗有关。
尽管接受了定期的肾病护理,但很少有透析前患者达到EBPG的Hb浓度目标。